An anti-copper drug compound that disables the ability of bone marrow cells from setting up a "home" in organs to receive and nurture migrating cancer tumor cells has shown surprising benefit in one of the most difficult-to-treat forms of cancer -- high-risk triple-negative breast cancer. The median survival for metastatic triple-negative breast cancer patients is historically nine months...
More...
More...